BMJ

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

1 University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ...
BMJ

Power Doppler ultrasonography and synovitis: correlating ultrasound imaging with histopathological findings and evaluating the performance of ultrasound equipments

1 Department of Internal Medicine, Mikkeli Central Hospital, Mikkeli, Finland 2 Department of Nuclear Medicine, Mikkeli Central Hospital, Mikkeli, Finland 3 Department of Pathology, Mikkeli Central ...
BMJ

Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis

Background: Although disease-specific health status measures are available for ankylosing spondylitis (AS), no instrument exists for assessing quality of life (QoL) in the condition. Objective: To ...
BMJ

Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke

2 Department of Medicine, Rheumatology Unit, Karolinska Institutet/Karolinska Hospital, Stockholm, Sweden 3 Unit of Clinical Immunology, Uppsala University/Akademiska Sjukhuset, Uppsala, Sweden 4 ...
BMJ

Dactylitis in psoriatic arthritis: a marker for disease severity?

1 The Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada 2 University of Toronto ...
BMJ

Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial

1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

Objectives To examine the safety and efficacy of rontalizumab, a humanised IgG1 anti-interferon α (anti-IFN-α) monoclonal antibody, in patients with moderate-to-severe systemic lupus erythematosus ...
BMJ

Lung involvement in primary Sjögren’s syndrome is mainly related to the small airway disease

Dr F N Skopouli, Department of Nutrition and Diatetics, Harokopio University, 70 El Venizelou Street, 176 71 Athens, Greece. METHODS Sixty one consecutive, non-smoking patients, 58 women and three men ...
BMJ

Paracetamol and cyclooxygenase inhibition: is there a cause for concern?

1 Institute of Toxicology and Pharmacology, University of Rostock, Rostock, Germany 2 Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University ...
BMJ

Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials

Correspondence to Dr Michael M Ward, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, NIAMS/NIH, Building 10 CRC, Room ...
BMJ

Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular ...

3 Institut National de la Santé et de la Recherche Medicale (INSERM CJF 96-02, IFR30), Purpan School of Medicine, University of Toulouse III, Toulouse, France 4 Department of Electrical Energy, ...
BMJ

Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs ...

Objective To assess the efficacy/safety of ivarmacitinib, a selective Janus kinase (JAK) 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate ...